Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $6.56 Million Registered Direct Offering
Press Release – New York, NY – January 25, 2021 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 1,250,000 American Depositary Shares (ADSs), each representing 600 of the Company’s ordinary shares, at a purchase price of $5.25 per ADS.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.
The Sichenzia Ross Ference LLP team was led by partners Darrin M. Ocasio, Avital Perlman and Jeffrey Cahlon and associate Yian Pan.
- Sichenzia Ross Ference LLP Represents Borqs Technologies, Inc. in $27 Million Private Placement - September 23, 2021
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp in $15 Million Registered Direct Offering of Molecular Data Inc. - September 22, 2021
- Sichenzia Ross Ference LLP Represents EzFill in $28.75 Million Initial Public Offering and NASDAQ Listing - September 20, 2021